Navigation Links
Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange

EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") Quest is pleased to provide an update on the pre-clinical development of SL052 for the treatment of prostate cancer.

Prostate cancer is the second leading cause of cancer death in American men with approximately 230,000 new cases and 30,000 deaths per year. Current therapeutic modalities for localized prostate cancer are associated with significant morbidity, such as sexual and urinary dysfunction. Photodynamic therapy (PDT) is a minimally invasive treatment that may be used in benign and malignant prostate diseases. PDT is a dual selective treatment modality using light of a specific wavelength to locally activate a photosensitizer accumulated in the target tissue. This novel therapy causes a non-carcinogenic photochemical destruction of cancer cells, including those that are resistant to radiation and chemotherapy.

Quest's innovative Photodynamic Therapy (PDT) prostate cancer treatment system utilizes our patented Sonolight Technology, our proprietary and potent Hypocrellin based photosensitizer, SL052, with a novel intra-arterial drug delivery system and state of the art laser device that delivers pulsed light. Pre-clinical studies in small and large animals have demonstrated the effectiveness of SL052 in selective destruction of normal and cancerous prostate tissues, with minimal side effects. The use of 18 F FDG (flurodeoxy glucose) PET imaging pre and post PDT treatment, highlighted the complete shut down of metabolic activity at the tumor site 24 hours after PDT treatment.

The practical application of this new PDT treatment system on the prostate gland has also been demonstrated using a canine prostate model. The intra-arterial drug delivery system allows the selective and significant accumulation of the photosensitizer in the prostate which is ea sily confirmed by fluorescence detection. PDT treatment of the prostate gland causes complete glandular tissue ablation within the intact capsule. Sexual and urological functions appear to be intact after the treatment with some acute voiding difficulties observed within the first few days.

Based on the exciting pre-clinical results, Quest will be compiling a pre-IND package, including chemical and manufacturing, toxicology, pharmacology and clinical protocol, and seek a pre-IND meeting with regulatory authorities as we progress this technology towards human clinical trials.

"We are very excited about the treatment results, and its potential as a first line therapy for prostate cancer. This warrants further testing of this new technology in a clinical setting," said Dr. Ron Moore, Professor of Surgery and Oncology, Faculty of Medicine, University of Alberta and Cross Cancer Institute.

SL052 for the treatment of prostate cancer is being developed in collaborations with Dr. Ron Moore and Dr. Jimmy Xiao of the Alberta Cancer Board, Dr. John Tulip at the Faculty of Engineering, University of Alberta and Dr. Dwayne Dickey, with support from the Alberta Ingenuity Fund and the National Research Council Canada, Industrial Research Assistance Program (NRC-IRAP).

The Company's lead photodynamic therapy product, SL017, is a topical formulation indicated for dermatology applications. The utility of SL017 has already been demonstrated for hair removal applications in a Phase I clinical trial. In Jan 2007, the Company initiated a fifty patient pivotal clinical trial for the same indications. In addition, SL017 is currently undergoing a Canadian Phase I clinical trial for Actinic Keratosis.

About Quest PharmaTech Inc.

The Corporation is a publicly traded , Alberta-based drug development company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cance r and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the

information contained herein."

CONTACT: Dr. Madi R.Madiyalakan, CEO, Tel.: (780) 448-1400 (Ext. 204),, Web site: www.questpharmatech.com madi@questpharmatech.com

Ticker Symbol: (:QPT.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. To Stent or Not: Is That the Question?
4. VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
7. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
10. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):